Kawabe, Yoshiki
Chugai Pharmaceutical Co., Ltd. (Japan)
3 papers on CoChatORCID 0000-0002-6465-7146
Most cited papers
- Verified
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., et al. (2020) · Proceedings of the National Academy of Sciences
Receptor Mechanisms and SignalingDiabetes Treatment and Management
Cited by 231
- Verified
Inhibin βE (INHBE) is a possible insulin resistance-associated hepatokine identified by comprehensive gene expression analysis in human liver biopsy samples
Sugiyama, M., Kikuchi, A., Misu, H., Igawa, H., Ashihara, M., Kushima, Y., Honda, K., Suzuki, Y., Kawabe, Y., Kaneko, S., et al. (2018) · PLoS ONE
Adipokines, Inflammation, and Metabolic DiseasesLiver Disease Diagnosis and Treatment
Cited by 52
- Verified
Inhibition of MEK1 signaling pathway in the liver ameliorates insulin resistance
Ueyama, A., Ban, N., Fukazawa, M., Hirayama, T., Takeda, M., Yata, T., Muramatsu, H., Hoshino, M., Yamamoto, M., Matsuo, M., et al. (2016) · Journal of Diabetes Research
Metabolism, Diabetes, and CancerDiabetes Treatment and Management
Cited by 7
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free